Alzheimer’s Disease remains one of the most complex challenges in drug development, with tau pathology playing a central role in neurodegeneration and cognitive decline. Multiple therapeutic strategies are being explored to target tau — but how do they compare, and which holds the greatest promise for meaningful clinical outcomes?
In this scientific poster, Certara researchers apply a quantitative systems pharmacology (QSP) framework to mechanistically model and compare distinct tau-targeting approaches across virtual patient populations.
What You’ll Learn:
- How QSP modeling can evaluate and differentiate tau-targeted therapeutic strategies, including antibodies, antisense oligonucleotides (ASOs), and post-translational modification (PTM) modifiers
- Why spatial accessibility within the synapse may limit the efficacy of anti-tau antibodies despite robust target engagement in CSF
- How APOE genotype and baseline disease stage influence predicted cognitive response to tau therapy
- The interplay between amyloid and tau pathology and its implications for treatment timing and patient selection
- Which intraneuronal tau-targeting mechanisms show the greatest predicted impact on disease biomarkers
Why It Matters:
Predicting which therapeutic strategy will translate to meaningful clinical benefit in Alzheimer’s Disease is a persistent challenge. This research demonstrates how mechanistic QSP modeling, grounded in real clinical biomarker and outcome data, can generate testable hypotheses, inform trial design, and enable head-to-head comparisons of current and emerging tau therapies. For sponsors developing tau-directed therapies, these insights can support more informed go/no-go decisions and smarter patient population selection.
